NLS Capital Stock from 2010 to 2024

Stocks . USA . 
Stock . NLS Pharmaceutics AG
NLSPW Stock  USD 0.01  0  27.27%   
NLS Pharmaceutics Capital Stock yearly trend continues to be fairly stable with very little volatility. Capital Stock will likely drop to about 397.9 K in 2024. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals
 
Capital Stock  
First Reported
2010-12-31
Previous Quarter
733.4 K
Current Value
397.9 K
Quarterly Volatility
204 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Interest Income of 681.3 K, Depreciation And Amortization of 9.8 K or Interest Expense of 137.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.
  
Check out the analysis of NLS Pharmaceutics Correlation against competitors.

Latest NLS Pharmaceutics' Capital Stock Growth Pattern

Below is the plot of the Capital Stock of NLS Pharmaceutics AG over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. NLS Pharmaceutics' Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NLS Pharmaceutics' overall financial position and show how it may be relating to other accounts over time.
Capital Stock10 Years Trend
Slightly volatile
Compare to OthersAll Fundamentals
   Capital Stock   
       Timeline  

NLS Capital Stock Regression Statistics

Arithmetic Mean242,431
Geometric Mean192,946
Coefficient Of Variation84.16
Mean Deviation156,609
Median133,544
Standard Deviation204,040
Sample Variance41.6B
Range599.9K
R-Value0.71
Mean Square Error22.5B
R-Squared0.50
Significance0
Slope32,236
Total Sum of Squares582.9B

NLS Capital Stock History

2024397.9 K
2023733.4 K
2022668.6 K
2021344.4 K
2019145.1 K

Other Fundumenentals of NLS Pharmaceutics

Issuance Of Capital Stock

NLS Pharmaceutics Capital Stock component correlations

Total Assets
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Long Term Debt
Capital Surpluse
Total Liab
Net Invested Capital
Total Current Assets
Net Working Capital
Common Stock
Net Receivables
Short Long Term Debt
Capital Stock
Short Term Debt
Current Deferred Revenue
Total Assets
0.89-0.78-0.460.07-0.330.3-0.630.420.990.610.530.130.460.60.380.51
Total Stockholder Equity
0.89-0.82-0.310.06-0.390.4-0.730.420.890.630.320.390.390.470.550.43
Net Debt
-0.78-0.820.74-0.580.84-0.820.810.15-0.73-0.1-0.69-0.59-0.77-0.75-0.48-0.8
Retained Earnings
-0.46-0.310.74-0.790.82-0.80.50.54-0.440.35-0.98-0.19-0.82-0.92-0.17-0.85
Accounts Payable
0.070.06-0.58-0.79-0.880.91-0.22-0.820.0-0.690.650.530.850.670.030.83
Long Term Debt
-0.33-0.390.840.82-0.88-0.980.660.66-0.260.46-0.69-0.69-0.82-0.67-0.32-0.84
Capital Surpluse
0.30.4-0.82-0.80.91-0.98-0.56-0.650.24-0.440.670.680.850.710.320.86
Total Liab
-0.63-0.730.810.5-0.220.66-0.560.05-0.61-0.18-0.47-0.5-0.36-0.39-0.57-0.43
Net Invested Capital
0.420.420.150.54-0.820.66-0.650.050.480.96-0.4-0.38-0.49-0.270.12-0.47
Total Current Assets
0.990.89-0.73-0.440.0-0.260.24-0.610.480.660.520.050.40.590.380.45
Net Working Capital
0.610.63-0.10.35-0.690.46-0.44-0.180.960.66-0.23-0.23-0.32-0.080.27-0.29
Common Stock
0.530.32-0.69-0.980.65-0.690.67-0.47-0.40.52-0.230.030.730.920.090.77
Net Receivables
0.130.39-0.59-0.190.53-0.690.68-0.5-0.380.05-0.230.030.390.090.220.38
Short Long Term Debt
0.460.39-0.77-0.820.85-0.820.85-0.36-0.490.4-0.320.730.390.780.361.0
Capital Stock
0.60.47-0.75-0.920.67-0.670.71-0.39-0.270.59-0.080.920.090.780.140.8
Short Term Debt
0.380.55-0.48-0.170.03-0.320.32-0.570.120.380.270.090.220.360.140.39
Current Deferred Revenue
0.510.43-0.8-0.850.83-0.840.86-0.43-0.470.45-0.290.770.381.00.80.39
Click cells to compare fundamentals

About NLS Pharmaceutics Financial Statements

NLS Pharmaceutics investors use historical fundamental indicators, such as NLS Pharmaceutics' Capital Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NLS Pharmaceutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Stock733.4 K397.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY